Jacobs Levy Equity Management
THRD

Jacobs Levy Equity Management’s Third Harmonic Bio THRD Stock Holding History

Jacobs Levy Equity Management’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,428
Closed -$214K – 1079
2023
Q3 		$214K Buy
+33,428
New +$204K ﹤0.01% 920

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management's THRD Position: Q4 2023 in Review

Jacobs Levy Equity Management sold out of Third Harmonic Bio (THRD) in Q4 2023, closing a stake of 33,428 shares — an estimated $214K sold.

Jacobs Levy Equity Management first reported a position in THRD in Q3 2023 and held it in 1 quarter. The position peaked at $214K in Q3 2023. 62 funds tracked by Wall St. Rank hold THRD as of Q4 2023.

  • Jacobs Levy Equity Management reported no remaining Third Harmonic Bio position as of Q4 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 33,428 Third Harmonic Bio shares in Q4 2023, an estimated $214K.
  • Jacobs Levy Equity Management first reported a position in Third Harmonic Bio in Q3 2023 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Third Harmonic Bio position peaked at $214K in Q3 2023.
  • 62 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q4 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2023, filed 14 Feb 2024.